Follow-up screening with Magnetic Resonance Imaging

Multifocality and Multicentricity

If a significant lesion is found with an initial mammogram, MRI is often used to check for multifocality (more than one mass on the same breast ) and multicentricity (presense of a mass or lesion on the contralateral breast). This is routinely done as a preoperative staging procedure. Multifocal and multicentric tumors are succesfully detected through magnetic resonance imaging about 80% of the time. By comparison, a mammogram reveals multifocal and multicentric tumors about 45% of the time, with supplementary ultrasound increasing the sensibility to approximately 63%.

 

breast MRI multifocal tumors

 

Follow-up of biopsy

Frequently a suspicious finding with a mammograph is followed-up with an appropriate biopsy. If a patient is classified as 'high risk' due to the discovery of lobular neoplasia or some other atypical celluar appearance, MRI may be used to reinforce a preliminary diagnosis.

 

suspicious breast MRI

 

Often a patient will present with a negative finding on a mammograph but a positive finding of axillary lymph node metastasis from biopsy samples from that region. In these cases MRI is used in a kind of 'reverse' investigation to discover the 'primary' tumor in the breast. The success rate for finding these 'occult' primary tumors in this manner is about 75%.

Post Operative use of Magnetic Resonance Imaging.

MRI is frequently used following surgical treatments to check for residual tumors. This is often performed within nine days of the intial surgery, but the most accurate readings are thought to occur after approximately 38-40 days. One of the challenges in the follow-up of lumpectomy, with or without radiation treatment, is that tumors are easily confused with predictable scar tissue development. A lumpectomy scar may contain vascularised granulation tissue up to 18 months following surgery. So there is a limited 'window' for accurate MRI investigations during this period. To avoid this potential confusion, best results are obtained no later than 5 weeks following the surgery. The success rate of MRI in differentiating scar from tumor recurrence is very high, 90% or more. Granulated scar tissue tends to be more regular and homogeneous around the surgery site, while cancerous cells tend to divide and spread in a somewhat random fashion. The use of post operative, follow-up MRI has been shown to 'alter' the original breast cancer treatment plans in up to 30% of cases.

 

Magnetic Resonance imaging following chemotherapy

The usefulnes of magnetic resonance imaging following chemotherapy remains unclear. There is consensus that MRI is useful for monitoring a patient's response to ongoing chemical therapy. By visually checking on the progress of the tumor, adjustments can be made to the drug regimen and the optimal timetable for surgical removal can to planned. A magnetic resonance image can clearly indicate the complete failure of the tumors response to chemotherapy if no change is evident. What MRI cannot definitively determine is whether or not there remains some microscopic residual disease at the end of a course of chemotherapy. Complete absense of carcinoma can only be determined through cellular analysis.

 

References

  1. Greenstein Orel S. MR Imaging of the Breast, Radiological Clinics of North America, Vol. 38, No 4, July 2000, p.899-913.
  2. Hlawatsch A, Teifke A, Schmidt M, Thelen M. Preoperative Assessment of Breast Cancer: Sonography Versus MR Imaging. AJR 2002; 179:1493-1501.
  3. Liberman L, Morris EA, Kim CM, Kaplan JB, Abramson AF, Menell JH, Van Zee KJ, Dershaw DD. MR Imaging Findings in the Contralateral Breast of Women with Recently Diagnosed Breast Cancer. AJR 2003; 180:333-341.
  4. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of the breast cancer. Radiology 2001; 220:13-30.
  5. Lee CH. Breast MRI: patient selection/Indication. Society of Breast Imaging, 7th Postgraduate Course, 2005; May 25-28, 45-51 Vancouver, BC, Canada.
  6. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR 2002; 179:1193-209.
  7. Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, Lattanzio V, Del Maschio A; Italian Trial for Breast MR in Multifocal/Multicentric Cancer. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol. (Oct. 2004) 183(4):1149-57.
  8. Swayampakula, AN., Dillw, S., Abraham, J.Role of MRI in Screening, Diagnosis and Management of Breast Cancer Expert Rev Anticancer Ther. 2008;8(5):811-817
  9. Esserman LJ, Kumar AS, Herrera AF et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J. Clin. Oncol.(2006) 24, 4603-4610
  10. Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann. Surg. Oncol. (2005) 12, 1045-1053
  11. Fischer U, Zachariae O, Baum F, von HD, Funke M, Liersch T. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer 1497. Eur Radiol. (2004);14:1725–1731.
  12. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003;10:381–388.
  13. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology.( 2008);246:116–24.
  14. Lee JM, Orel SG, Czerniecki BJ, Solin LJ, Schnall MD. MRI before reexcision surgery in patients with breast cancer. AJR Am J Roentgenol.(Feb.2004) 182(2):473-80.
  15. Hylton, N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am (2006); 14:383.
  16. Esserman, L, Hylton, N, George, T, Weidner, N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J (1999); 5:13.
  17. Zakhireh, J, Gomez, R, Esserman, L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer (2008); 44:2742.

home

Copyright Steven B. Halls, MD Last edited 06-December-2010

breast-cancer.ca is brought to you by halls.md